Sphera Funds Management LTD. cut its position in shares of Ignyta Inc (NASDAQ:RXDX) by 25.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 344,300 shares of the biopharmaceutical company’s stock after selling 115,000 shares during the quarter. Ignyta accounts for 1.1% of Sphera Funds Management LTD.’s portfolio, making the stock its 18th largest position. Sphera Funds Management LTD. owned about 0.51% of Ignyta worth $9,193,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. lifted its stake in Ignyta by 28.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,745 shares of the biopharmaceutical company’s stock valued at $1,219,000 after buying an additional 26,100 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in Ignyta by 123.9% during the second quarter. TIAA CREF Investment Management LLC now owns 287,394 shares of the biopharmaceutical company’s stock valued at $2,975,000 after buying an additional 159,055 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in Ignyta during the fourth quarter valued at about $1,898,000. American Century Companies Inc. purchased a new stake in Ignyta during the third quarter valued at about $2,842,000. Finally, Crestline Management LP lifted its stake in Ignyta by 44.3% during the third quarter. Crestline Management LP now owns 133,584 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 41,023 shares in the last quarter. 72.28% of the stock is owned by institutional investors.
Shares of Ignyta Inc (NASDAQ:RXDX) opened at $26.95 on Thursday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.34. The stock has a market cap of $1,790.00, a P/E ratio of -9.94 and a beta of 184.87. Ignyta Inc has a 52-week low of $5.80 and a 52-week high of $27.10.
A number of research firms have commented on RXDX. Zacks Investment Research raised shares of Ignyta from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research note on Wednesday, January 10th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $27.00 price objective on shares of Ignyta in a research note on Friday, February 9th. ValuEngine raised shares of Ignyta from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Jefferies Group lowered shares of Ignyta from a “buy” rating to a “hold” rating and set a $27.00 price objective for the company. in a research note on Thursday, December 28th. Finally, Ladenburg Thalmann Financial Services lowered shares of Ignyta from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 26th. Seven research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Ignyta currently has a consensus rating of “Hold” and a consensus target price of $27.00.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/sphera-funds-management-ltd-has-9-19-million-holdings-in-ignyta-inc-rxdx.html.
Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.
Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ignyta Inc (NASDAQ:RXDX).
Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.